In addition, there was a poorer prognosis and shorter disease-free survival (DFS) rate among patients with multiple tumors who had high levels of SHOX2 mRNA expression, including ACC, KIRC, KIRP and LGG (Fig. 2B). This evidence concerns the gene SHOX2 and adrenal cortex carcinoma.